These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 2132052)

  • 1. [Clinical trial of the treatment of amyotrophic lateral sclerosis with bromocriptine].
    Szulc-Kuberska J; Klimek A; Stepień H; Woszczak M
    Neurol Neurochir Pol; 1990; 24(1-2):37-41. PubMed ID: 2132052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Amyotrophic lateral sclerosis].
    Iwanowski L
    Neurol Neurochir Pol; 1999; 33(2):445-50. PubMed ID: 10463257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of bromocriptine and metoclopramide on serum prolactin levels in patients with amyotrophic lateral sclerosis.
    Szulc-Kuberska J; Stepień H; Klimek A; Cieślak D
    J Neurol Neurosurg Psychiatry; 1988 May; 51(5):643-5. PubMed ID: 3404163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of amyotrophic lateral sclerosis with TRH].
    Klimek A; Szulc-Kuberska J; Czernielewska-Rutkowska I; Głuszcz-Zielińska A
    Neurol Neurochir Pol; 1988; 22(3):206-10. PubMed ID: 3146705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjunctive therapy with bromocriptine in Parkinson's disease.
    Temlett JA; Ming A; Saling M; Fritz VU; Blumenfeld A; Bilchik TR; Becker AL; Fourie PB; Reef HE
    S Afr Med J; 1990 Dec; 78(11):680-5. PubMed ID: 2251616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain dopamine receptor stimulation and the relief of Parkinsonism: relationship between bromocriptine and levodopa.
    Rinne UK; Marttila R
    Ann Neurol; 1978 Sep; 4(3):263-7. PubMed ID: 718139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of a selective partial D1 agonist, CY 208-243, in de novo patients with Parkinson disease.
    Emre M; Rinne UK; Rascol A; Lees A; Agid Y; Lataste X
    Mov Disord; 1992; 7(3):239-43. PubMed ID: 1535688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolactin resistance to bromocryptine treatment: a case report.
    Borenstein R; Kessler I; Ben-David M
    Int J Fertil; 1981; 26(4):287-9. PubMed ID: 6120911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, tolerability, and cerebrospinal fluid penetration of ursodeoxycholic Acid in patients with amyotrophic lateral sclerosis.
    Parry GJ; Rodrigues CM; Aranha MM; Hilbert SJ; Davey C; Kelkar P; Low WC; Steer CJ
    Clin Neuropharmacol; 2010; 33(1):17-21. PubMed ID: 19935406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of adding the D1 agonist CY 208-243 to chronic bromocriptine treatment. I: Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors.
    Gomez-Mancilla B; Boucher R; Gagnon C; Di Paolo T; Markstein R; Bédard PJ
    Mov Disord; 1993 Apr; 8(2):144-50. PubMed ID: 8474480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bromocriptine in Parkinson disease.
    Lieberman AN; Goldstein M
    Pharmacol Rev; 1985 Jun; 37(2):217-27. PubMed ID: 3901046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Riluzole exerts central and peripheral modulating effects in amyotrophic lateral sclerosis.
    Vucic S; Lin CS; Cheah BC; Murray J; Menon P; Krishnan AV; Kiernan MC
    Brain; 2013 May; 136(Pt 5):1361-70. PubMed ID: 23616585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Experience with the use of parlodel in the treatment of Parkinson patients].
    Stoliarova LG; Kadykov AS; Shvedkov VV; Pivovarova VM
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1986; 86(2):219-22. PubMed ID: 3705825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of amyotrophic lateral sclerosis with thyrotropin releasing hormone].
    Serratrice G; Desnuelle C; Crevat A; Guelton C; Meyer-Dutour A
    Rev Neurol (Paris); 1986; 142(2):133-9. PubMed ID: 3088700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma dopamine beta hydroxylase activity in chronic schizophrenic patients tested with single dose of 2-bromo-alpha ergocriptine (Parlodel).
    Vardi J; Flechter S; Oberman Z; Segal R; Shogan G; Haker O
    Encephale; 1981; 7(1):95-103. PubMed ID: 7227288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose bromocriptine in the early phases of Parkinson's disease.
    Tolosa E; Blesa R; Bayes A; Forcadell F
    Clin Neuropharmacol; 1987 Apr; 10(2):168-74. PubMed ID: 3332610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amyotrophic lateral sclerosis: alterations in neurotransmitter receptors.
    Whitehouse PJ; Wamsley JK; Zarbin MA; Price DL; Tourtellotte WW; Kuhar MJ
    Ann Neurol; 1983 Jul; 14(1):8-16. PubMed ID: 6137185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term treatment of acromegaly with bromocryptine: postprandial HGH levels and response to TRH and glucose administration.
    Benker G; Zäh W; Hackenberg K; Hamburger B; Günnewig H; Reinwein D
    Horm Metab Res; 1976 Jul; 8(4):291-5. PubMed ID: 182633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A clinical trial of verapamil in amyotrophic lateral sclerosis.
    Miller RG; Smith SA; Murphy JR; Brinkmann JR; Graves J; Mendoza M; Sands ML; Ringel SP
    Muscle Nerve; 1996 Apr; 19(4):511-5. PubMed ID: 8622731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.